Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686518 | 0.85 | OPRM1 (0.39) | GRIN1GRIN2BLMNA | |
| SCHEMBL4689021 | 0.82 | GRIN1 (0.40) | GRIN1GRIN2BLMNA | |
| SCHEMBL4689099 | 0.78 | HSD11B1 (0.42) | GRIN1GRIN2BLMNA | |
| SCHEMBL4398729 | 0.73 | MGLL (0.36) | LMNA | |
| SCHEMBL7879929 | 0.71 | GRIN1 (0.40) | GRIN1GRIN2B | |
| SCHEMBL2083953 | 0.71 | CA12 (0.39) | LMNA | |
| SCHEMBL3395753 | 0.70 | GRIN1 (0.41) | GRIN1GRIN2B | |
| SCHEMBL21143386 | 0.66 | TSHR (0.41) | LMNA | |
| SCHEMBL274635 | 0.66 | DGKA (0.42) | LMNA | |
| SCHEMBL21143363 | 0.66 | ADRA2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004639-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | Teva Pharmaceutical Industries Ltd (IL) | 2008-12-24 | — | — | EP | disclosed |
| US-20080032964-A1 | Process for the synthesis of azetidinone | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007120824-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032964-A1 | Process for the synthesis of azetidinone | CYP46A1, APOB, CYP51A1 | GRIN1 3842/4885GRIN2B 2817/4885LMNA 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.